Sierra Oncology is a clinical stage drug development company advancing targeted DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer. The company’s lead drug candidate, SRA737, is a highly […]

ProLung’s mission is to improve outcomes for potential lung cancer patients through early predictive technologies, provide cost savings to patients, payers, and providers, and to provide a fair return on investment to […]

Fusion Genomics is a company that is working to advance molecular diagnostics through developing tests for pathogens that cause disease. They do this using proprietary technologies in combination with Next Generation Sequencing. […]

Leap Therapeutics, Inc. (LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, recently reported financial results for the year ended December 31, 2016 and top-line progression-free survival (PFS) data. Earlier this year, Leap […]

Genprex is a clinical-stage biopharmaceutical company developing targeted molecular therapies for cancer. The company is developing molecular therapies that control universal cancer pathways to unlock the unrealized potential of targeted cancer therapies, such […]

Interpace Diagnostics is a company focused on the development and commercialization of molecular diagnostic tests aimed to optimize patient diagnosis and management. The company currently has three commercialized molecular tests: (1) PancraGen, […]

Biocept is a diagnostic company that focuses on developing solutions aimed to optimize outcomes for cancer patients. Their most recent diagnostic comes in the form of a liquid biopsy, developed in an […]

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company in Boston, is developing Anticalin-based drugs for the treatment of cancer, asthma, anemia and other conditions that show a high unmet medical need. Pieris’ […]